The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) solicits applications to participate in the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. The purpose of this FOA is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties. This FOA solicits for Centers proposing research on virus families from Flaviviridae and Togaviridae to be part of the ReVAMPP Network.
The ReVAMPP Network is comprised of ReVAMPP Centers from this FOA (Flaviviridae and Togaviridae) and its companion FOAs soliciting for ReVAMPP Centers focusing on Bunyavirales, Paramyxoviridae and Picornaviridae (see RFA-AI-23-020) and the ReVAMPP Coordinating and Data Sharing Center (CDSC) (see RFA-AI-23-021). ReVAMPP Centers will conduct independent research project(s) and are expected to share information and collaborate under the direction of the ReVAMPP CDSC which is responsible for establishing and maintaining a collaborative ReVAMPP Network platform for data sharing and overall collaboration among the ReVAMPP Centers.
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Date: June 8, 2023
RFA-AI-23-019 Expiration Date June 09, 2023
Applicants listed as PD(s)/PI(s) for this FOA will not be eligible to be listed as PI(s)/PD(s) on applications submitted to the companion FOA (RFA-AI-23-020) ReVAMPP Centers for Bunyavirales, Paramxyoviridae, and Picornaviridae, but can participate as collaborators on subcomponents of those Centers. Applicants to this FOA will not be eligible to submit to or participate in the companion ReVAMPP CDSC FOA (RFA-AI-23-021) due to the centralized role of the CDSC in the Network Coordination and communication.
Application budgets are not expected to exceed $10M direct costs/year and need to reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum period is 5 years.